14/07/2026 Innovent Biologics and Spero Therapeutics announced an exclusive licensing agreement for IBI355 for the treatment of immune-mediated diseases Innovent Biologics and Spero Therapeutics announced an exclusive licensing agreement for IBI355 for the treatment of immune-mediated diseases (Ref) Innovent Biologics and Spero Therapeutics announced an exclusive license agreement for IBI355 (SP001; a third-generation Fc-silent anti-CD40L antibody) for immune-mediated disease